to assess the relationship between plasma levels of 2,5-bis- ( 2,2,2-trifluoroethoxy ) -n- ( 2-piperidylmethyl ) benz-amide acetate ( flecainide acetate ) , a new antiarrhythmic , and the suppression of ventricular arrhythmias , a decreasing multiple oral dosage regimen ( 200 mg b.i.d . to 50 mg b.i.d . ) was administered over 12 days to eight patients with chronic ventricular extrasystoles .
C0086303
flecainide acetate
C0003195
antiarrhythmic